Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells

Progressive bladder cancer growth is associated with abnormal activation of the mammalian target of the rapamycin (mTOR) pathway, but treatment with an mTOR inhibitor has not been as effective as expected. Rather, resistance develops under chronic drug use, prompting many patients to lower their rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Justin, Saira, Rutz, Jochen, Maxeiner, Sebastian, Chun, Felix K.-H., Juengel, Eva, Blaheta, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312500/
https://www.ncbi.nlm.nih.gov/pubmed/32512849
http://dx.doi.org/10.3390/ijms21114026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312500/
https://www.ncbi.nlm.nih.gov/pubmed/32512849
http://dx.doi.org/10.3390/ijms21114026

Ejemplares similares